XML 31 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 135 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
Costs and expenses:      
Research and development $ 181 $ 422 $ 42,858
Selling, general and administrative 889 984 43,472
Merger transaction costs     5,470
Restructuring expense, net     2,413
Loss on impairment of in-process research and development     6,000
Total costs and expenses 1,070 1,406 100,213
Loss from operations (1,070) (1,406) (100,213)
Gain on assignment of patent rights     2,000
Gain on bargain purchase     25,282
Interest and other income     2,028
Interest and other expense (1) (1) (443)
Loss before income taxes (1,071) (1,407) (71,346)
Benefit from income taxes     2,281
Net loss and comprehensive loss (1,071) (1,407) (69,065)
Less: Accretion of redeemable convertible preferred stock     (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions     (781)
Net loss attributable to common stockholders $ (1,071) $ (1,407) $ (70,091)
Net loss attributable to common stockholders per share:      
Basic and diluted $ (0.35) $ (0.69)  
Weighted average shares outstanding:      
Basic and diluted 3,034,763 2,027,716